Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

Gabapentin and pregabalin are now controlled drugs

1st April 2019

Gabapentin and pregabalin were reclassified as Schedule 3 controlled drugs, on 1 April 2019, under the Misuse of Drugs Regulations 2001 (see our previous news item), with exemption from safe custody.

Full controlled drug prescription writing and requisition requirements for Schedule 3 controlled drugs are required for supply. However, gabapentin and pregabalin do not need to be stored in a separate locked controlled drug cabinet. Information and answers to frequently asked questions are available on the Royal Pharmaceutical Society support alert.

Click here to view